



Docket No. 58098 (71417)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application: Douglas W. Losordo  
Raj Kishore Examiner: Not Yet Assigned

Serial No. 10/633,407 Group: Not Yet Assigned

Filed: August 1, 2003

For: CELL MODULATION USING CYTOSKELETAL PROETIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

---

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 9/26/03.

By: Lee Dunkle

---

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

a. X Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

a. \_\_\_\_\_ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).

b. \_\_\_\_\_ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

c. \_\_\_\_\_ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)  
(check one box)

a. \_\_\_\_\_ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

b. \_\_\_\_\_ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

c. X before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):  
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

a. \_\_\_\_\_ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

or

b. \_\_\_\_\_ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e)  
(check only one box)

The undersigned hereby certified that

a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(d)

☐ after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

a. ☐ after the mailing date of a Final Office Action under 37 C.F.R. § 1.113

b. ☐ see certificate above

c. ☐ a fee in the amount of \$180.00 is required by 37 CFR § 1.17(p)

d. ☐ applicant hereby petitions that this Information Disclosure Statement is considered in accordance with 37 C.F.R. § 1.97(d).

Enclosed is a check in the amount of \$180.00 for the above-indicated fee. Should any further fee be associated with the submission of this Information Disclosure Statement, the Commissioner is authorized to charge our Deposit Account No. 04-1105.

  X   No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,

Date 26 Sept 03



Robert L. Buchanan  
Registration No. 40,927  
EDWARDS & ANGELL, LLP  
P.O. Box 9169  
Boston, MA 02209  
(617) 439-4444

# **INFORMATION DISCLOSURE CITATION** (Use several sheets if necessary)

Docket Number (Optional)  
**58098 (71417)**

Application Number  
**10/633,407**

Applicant(s)  
**L sordo, et al.**

Filing Date  
**August 1, 2003**

Group Art Unit  
**Not Yet Assigned**

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,773,573	6/30/98	Holms			
	AB	6,399,584	6/6/02	Arpin et al.			
	AC	6,225,442	5/1/01	Wagatsuma et al.			
	AD	6,451,825	9/17/02	Uehata et al.			
	AE	6,218,410	4/17/02	Uehata et al.			
	AF	6,416,757	7/9/02	Rathjen et al.			
	AG	6,379,666	4/30/02	Tobinick			
	AH	6,107,273	8/22/00	Jameson et al.			
	AI	6,015,557	1/18/00	Tobinick et al.			
	AJ	6,399,377	6/4/02	Mory			

## **FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	BA	6 289679	10/18/94	Japan			Abstract	
	BB	5 194401	8/3/93	Japan			Abstract	
	BC	4 273821	9/30/92	Japan			Abstract	
	BD	3 218356	9/25/91	Japan			Abstract	
	BE	WO95/28387	10/26/95	PCT			Abstract	

## **OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Beutler, B. J. Investig. Med. 1995; 43:227-35
	CB	Liu, N. et al. Nucleic Acids Res. 1997; 25:4915--20

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Docket Number (Optional)  
**58098**

Application Number  
**10/633,407**

Applicant(s)  
**Losordo, et al.**

Filing Date  
**August 1, 2003**

Group Art Unit  
**Not Yet Assigned**

\*EXAMINER  
INITIAL

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

CC

Schulze, A. et al. PNAS (USA) 92: 11264-11268 (1995)

CD

Philips, A. et al. (1999) Oncogene 18: 6222-6232

CE

Turunen, O. et al., J. Biol. Chem., 264: pp. 16727-16732, (1989)

CF

Funayama, N. et al., J. Cell Biol., Vol. 115, P. 1039-1048, (1991)

CG

Lankes, W. T. et al., PNAS (USA) pp. 8297-8301, (1991)

CH

Gould et al. EMBO J. 8:4133-4142 (1989)

CI

Martin, et al. J. Cell Biol. 128: 1081-1093 (1995)

CJ

Algrain M. et al. J. Cell Biol. 120: 129-139 (1993)

CK

Krasinski K, Spyridopoulos I, Kearney M, Losordo DW, Circulation 2001; 104: 1754-1756

CL

Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Circulation. 1997; 95:1505-1514

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.